Efficacy of regimens combining direct acting antiviral agents for hepatitis C virus recombinant form RF1_2k/1b

被引：1

作者：

Matsuura, Kentaro ^{[1
]}

Tanaka, Yasuhito ^{[2
]}

机构：

[1] Nagoya City Univ, Dept Gastroenterol & Metab, Grad Sch Med Sci, Nagoya, Aichi, Japan

[2] Nagoya City Univ, Dept Virol & Liver Unit, Grad Sch Med Sci, Nagoya, Aichi, Japan

来源：

HEPATOLOGY RESEARCH | 2018年 / 48卷 / 01期

关键词：

INTERGENOTYPIC RECOMBINANT; MOLECULAR EPIDEMIOLOGY; 2K/1B; SOFOSBUVIR; RIBAVIRIN; GENOTYPES; STRAINS;

D O I：

10.1111/hepr.12903

中图分类号：

R57 [消化系及腹部疾病];

学科分类号：

摘要：

引用

页码：3 / 4

页数：2

共 50 条

[21] Versant HCV Genotype 2.0 assay (LiPA) misclassifies the circulating HCV recombinant RF1_2k/1b in genotype 2 patients
Orlent, Hans
Schuermans, Wim
Padalko, Elizaveta
Desombere, Isabelle
Descheemaeker, Patrick
Van Vlierberghe, Hans
Reynders, Marijke
HEPATOLOGY, 2016, 64 : 404A - 404A
[22] Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-naive Patients Infected with Genotype 1b Hepatitis C Virus
Wang, Ye
Rao, Hui-Ying
Xie, Xing-Wang
Wei, Lai
CHINESE MEDICAL JOURNAL, 2015, 128 (19) : 2625 - 2631
[23] Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C
Izzo, Ilaria
Zanotti, Paola
Chirico, Claudia
Casari, Salvatore
Villanacci, Vincenzo
Salemme, Marianna
Biasi, Luciano
Festa, Elena
Castelli, Francesco
INFECTION, 2016, 44 (06) : 811 - 812
[24] Colitis during new direct-acting antiviral agents (DAAs) therapy with sofosbuvir, simeprevir and ribavirin for genotype 1b hepatitis C
Ilaria Izzo
Paola Zanotti
Claudia Chirico
Salvatore Casari
Vincenzo Villanacci
Marianna Salemme
Luciano Biasi
Elena Festa
Francesco Castelli
Infection, 2016, 44 : 811 - 812
[25] Direct-acting Antiviral Agents Resistance-associated Polymorphisms in Chinese Treatment-na?ve Patients Infected with Genotype 1b Hepatitis C Virus
Wang Ye
Rao Hui-Ying
Xie Xing-Wang
Wei Lai
中华医学杂志英文版, 2015, 128 (19) : 2625 - 2631
[26] Four-Week Direct-Acting Antiviral Regimens in Noncirrhotic Patients With Hepatitis C Virus Genotype 1 Infection
Kohli, Anita
Kattakuzhy, Sarah
Sidharthan, Sreetha
Nelson, Amy
McLaughlin, Mary
Seamon, Cassie
Wilson, Eleanor
Meissner, Eric G.
Sims, Zayani
Silk, Rachel
Gross, Chloe
Akoth, Elizabeth
Tang, Lydia
Price, Angie
Jolley, Tim A.
Emmanuel, Benjamin
Proschan, Michael
Teferi, Gebeyehu
Chavez, Jose
Abbott, Stephen
Osinusi, Anuoluwapo
Mo, Hongmei
Polis, Michael A.
Masur, Henry
Kottilil, Shyam
ANNALS OF INTERNAL MEDICINE, 2015, 163 (12) : 899 - +
[27] Efficacy and Tolerability of Direct-Acting Antiviral Agents for Hepatitis C Virus Infection in Kidney Transplant Recipients
Suna, Nuretdin
Etik, Digdem Ozer
Ocal, Serkan
Selcuk, Haldun
Dagli, Ulku
Hilmioglu, Fatih
Boyacioglu, Sedat
Haberal, Mehmet
TRANSPLANTATION, 2018, 102 : S909 - S909
[28] High incidence of the hepatitis C virus recombinant 2k/1b in Georgia: Recommendations for testing and treatment
Karchava, Marine
Waldenstrom, Jesper
Parker, Monica
Hallack, Renee
Sharvadze, Lali
Gatserelia, Lana
Chkhartishvili, Nikoloz
Dvali, Natia
Dzigua, Lela
Dolmazashvili, Ekaterine
Norder, Helene
Tsertsvadze, Tengiz
HEPATOLOGY RESEARCH, 2015, 45 (13) : 1292 - 1298
[29] Direct-Acting Antiviral Agents for Patients With Hepatitis C Virus Genotype 1 Infection Are Cost-Saving
Chhatwal, Jagpreet
He, Tianhua
Hur, Chin
Lopez-Olivo, Maria A.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2017, 15 (06) : 827 - +
[30] COMPARISON OF THE EFFICACY AND SAFETY OF DIRECT-ACTING ANTIVIRAL AGENTS IN THE TREATMENT OF HEPATITIS C VIRUS GENOTYPE 1 BETWEEN THE TURKISH ELDERLY AND YOUNGER POPULATION
Adanir, Haydar
Akin, Mete
Alkan, Erhan
TURKISH JOURNAL OF GERIATRICS-TURK GERIATRI DERGISI, 2022, 25 (01): : 68 - 78

← 1 2 3 4 5 →